BR112021024966A2 - Composições e métodos para administração subcutânea de imunoterapia de câncer - Google Patents
Composições e métodos para administração subcutânea de imunoterapia de câncerInfo
- Publication number
- BR112021024966A2 BR112021024966A2 BR112021024966A BR112021024966A BR112021024966A2 BR 112021024966 A2 BR112021024966 A2 BR 112021024966A2 BR 112021024966 A BR112021024966 A BR 112021024966A BR 112021024966 A BR112021024966 A BR 112021024966A BR 112021024966 A2 BR112021024966 A2 BR 112021024966A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- subcutaneous administration
- compositions
- cancer immunotherapy
- cancer
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000007920 subcutaneous administration Methods 0.000 title abstract 3
- 238000002619 cancer immunotherapy Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 230000000116 mitigating effect Effects 0.000 abstract 1
- 230000000737 periodic effect Effects 0.000 abstract 1
- 210000003289 regulatory T cell Anatomy 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
composições e métodos para administração subcutânea de imunoterapia de câncer. a presente invenção fornece composições, métodos e regimes de tratamento para o tratamento de câncer compreendendo a administração subcutânea periódica da proteína de fusão de seq id no: 1 a um paciente com câncer resultando em ativação intensificada de células t cd8+ com efeitos mínimos na expansão de células t reguladoras (treg) e fornecer eficácia anti-tumoral melhorada ao mesmo tempo que mitiga a inativação/exaustão de células t.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962860182P | 2019-06-11 | 2019-06-11 | |
US201962924356P | 2019-10-22 | 2019-10-22 | |
US201962932160P | 2019-11-07 | 2019-11-07 | |
PCT/EP2020/066234 WO2020249693A1 (en) | 2019-06-11 | 2020-06-11 | Compositions and methods for subcutaneous administration of cancer immunotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021024966A2 true BR112021024966A2 (pt) | 2022-02-15 |
Family
ID=71092539
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021024966A BR112021024966A2 (pt) | 2019-06-11 | 2020-06-11 | Composições e métodos para administração subcutânea de imunoterapia de câncer |
BR112021025035A BR112021025035A2 (pt) | 2019-06-11 | 2020-06-11 | Composições e métodos para imunoterapia contra câncer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021025035A BR112021025035A2 (pt) | 2019-06-11 | 2020-06-11 | Composições e métodos para imunoterapia contra câncer |
Country Status (12)
Country | Link |
---|---|
US (3) | US20210038684A1 (pt) |
EP (2) | EP3982998A1 (pt) |
JP (2) | JP2022535610A (pt) |
KR (2) | KR20220044480A (pt) |
CN (2) | CN114555126A (pt) |
AU (2) | AU2020292590A1 (pt) |
BR (2) | BR112021024966A2 (pt) |
CA (2) | CA3143097A1 (pt) |
IL (2) | IL288754A (pt) |
MA (1) | MA56176A (pt) |
MX (2) | MX2021015353A (pt) |
WO (2) | WO2020249693A1 (pt) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210038684A1 (en) | 2019-06-11 | 2021-02-11 | Alkermes Pharma Ireland Limited | Compositions and Methods for Cancer Immunotherapy |
WO2021074689A1 (en) * | 2019-10-18 | 2021-04-22 | Alkermes Pharma Ireland Limited | Immunomodulatory il-2 agents in combination with immune checkpoint inhibitors |
WO2021211857A1 (en) * | 2020-04-15 | 2021-10-21 | Alkermes Pharma Ireland Limited | Immunostimulatory agents in combination with angiogenesis inhibitors |
MX2022012982A (es) * | 2020-04-15 | 2023-03-06 | Alkermes Pharma Ireland Ltd | Agentes inmunoestimulantes en combinación con inhibidores de la angiogénesis. |
CA3176356A1 (en) | 2020-04-22 | 2021-10-28 | Anne BROOKS | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
US20230293685A1 (en) | 2020-05-04 | 2023-09-21 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
JP2023523855A (ja) | 2020-05-04 | 2023-06-07 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用 |
KR20230009446A (ko) * | 2020-05-11 | 2023-01-17 | 엘커메스 파마 아일랜드 리미티드 | Il-2 융합 폴리펩티드 조성물 및 그의 제조 및 사용 방법 |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
EP4225330A1 (en) | 2020-10-06 | 2023-08-16 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
US20240131064A1 (en) | 2020-12-11 | 2024-04-25 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
JP2024500403A (ja) | 2020-12-17 | 2024-01-09 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 腫瘍浸潤リンパ球によるがんの治療 |
EP4262811A1 (en) | 2020-12-17 | 2023-10-25 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
EP4271791A2 (en) | 2020-12-31 | 2023-11-08 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
JP2024506557A (ja) | 2021-01-29 | 2024-02-14 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 修飾された腫瘍浸潤リンパ球を作製する方法及び養子細胞療法におけるそれらの使用 |
EP4288140A1 (en) | 2021-02-05 | 2023-12-13 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
CA3210755A1 (en) | 2021-03-05 | 2022-09-09 | Kenneth ONIMUS | Tumor storage and cell culture compositions |
WO2022198141A1 (en) | 2021-03-19 | 2022-09-22 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils |
US20220313806A1 (en) | 2021-03-25 | 2022-10-06 | Iovance Biotherapeutics, Inc. | Methods and compositions for t-cell coculture potency assays and use with cell therapy products |
CN117321087A (zh) | 2021-03-26 | 2023-12-29 | 先天制药公司 | 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质 |
WO2022212948A1 (en) * | 2021-04-02 | 2022-10-06 | Duke University | Methods for determining tumor immune status |
BR112023021665A2 (pt) | 2021-04-19 | 2023-12-19 | Iovance Biotherapeutics Inc | Método para tratar um câncer, e, composição |
CA3219148A1 (en) | 2021-05-17 | 2022-11-24 | Frederick G. Vogt | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
CN117616050A (zh) | 2021-06-09 | 2024-02-27 | 先天制药公司 | 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质 |
WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
WO2023004074A2 (en) | 2021-07-22 | 2023-01-26 | Iovance Biotherapeutics, Inc. | Method for cryopreservation of solid tumor fragments |
TW202327631A (zh) | 2021-07-28 | 2023-07-16 | 美商艾歐凡斯生物治療公司 | 利用腫瘤浸潤性淋巴球療法與kras抑制劑組合治療癌症患者 |
IL311333A (en) | 2021-09-09 | 2024-05-01 | Iovance Biotherapeutics Inc | Processes for the production of TIL products using a strong PD-1 TALEN |
CA3232700A1 (en) | 2021-09-24 | 2023-03-30 | Rafael CUBAS | Expansion processes and agents for tumor infiltrating lymphocytes |
AR127482A1 (es) | 2021-10-27 | 2024-01-31 | Iovance Biotherapeutics Inc | Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente |
WO2023086803A1 (en) | 2021-11-10 | 2023-05-19 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
WO2023147486A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
WO2023154894A2 (en) * | 2022-02-11 | 2023-08-17 | Alkermes Pharma Ireland Limited | Compositions and methods for cancer immunotherapy |
EP4241791A1 (en) | 2022-03-07 | 2023-09-13 | InnaTher Gene Therapy S.à.r.l. | Combined gene and radio therapy for the treatment of cancer |
EP4241790A1 (en) | 2022-03-07 | 2023-09-13 | InnaTher Gene Therapy S.à.r.l. | Expression system for the treatment of cancer |
WO2023196877A1 (en) | 2022-04-06 | 2023-10-12 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
WO2023220608A1 (en) | 2022-05-10 | 2023-11-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist |
WO2024011114A1 (en) | 2022-07-06 | 2024-01-11 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
CN117003852A (zh) * | 2022-07-07 | 2023-11-07 | 北京大学 | 白细胞介素-2的拓扑改造及其作为自身免疫病药物的应用 |
WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
WO2024055018A1 (en) | 2022-09-09 | 2024-03-14 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
WO2024055017A1 (en) | 2022-09-09 | 2024-03-14 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
WO2024098027A1 (en) | 2022-11-04 | 2024-05-10 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5766920A (en) | 1982-08-11 | 1998-06-16 | Cellcor, Inc. | Ex vivo activation of immune cells |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
CN1007907B (zh) * | 1985-04-30 | 1990-05-09 | 弗·哈夫曼-拉罗彻有限公司 | 重组人类白细胞介素-2的提纯 |
AU7873187A (en) | 1986-08-08 | 1988-02-24 | University Of Minnesota | Method of culturing leukocytes |
US5126132A (en) | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
AU7478394A (en) | 1993-08-06 | 1995-02-28 | Cytel Corporation | Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
CA2214649C (en) | 1995-03-08 | 2007-06-12 | Zeling Cai | Antigen presenting system and methods for activation of t-cells |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
AU738538B2 (en) | 1997-01-31 | 2001-09-20 | Hemosol Inc. | Method for the production of selected lymphocytes |
JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド | 免疫療法のctla−4結合ペプチド |
US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
KR100856446B1 (ko) | 1998-12-23 | 2008-09-04 | 화이자 인크. | Ctla-4에 대한 인간 단일클론 항체 |
ES2282133T3 (es) | 1999-08-24 | 2007-10-16 | Medarex, Inc. | Anticuerpos frente a la ctla-4 humano y sus usos. |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
AU3402501A (en) | 2000-03-02 | 2001-09-12 | Univ Southern California | Mutated cyclin g1 protein |
KR20090125840A (ko) | 2001-06-13 | 2009-12-07 | 젠맵 에이/에스 | 표피 성장 인자 수용체 (egfr)에 대한 인간 모노클로날 항체 |
US7354928B2 (en) | 2001-11-01 | 2008-04-08 | The Regents Of The University Of Michigan | Small molecule inhibitors targeted at Bcl-2 |
AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
AU2003288675B2 (en) | 2002-12-23 | 2010-07-22 | Medimmune Limited | Antibodies against PD-1 and uses therefor |
US7402431B2 (en) | 2004-03-01 | 2008-07-22 | Immunovative Therapies, Ltd. | T-cell therapy formulation |
US7435592B2 (en) | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
JP2007501243A (ja) | 2003-08-04 | 2007-01-25 | ブリストル−マイヤーズ スクイブ カンパニー | 可溶性ctla4分子を用いる心臓血管疾患の治療方法 |
US20060057121A1 (en) | 2004-09-10 | 2006-03-16 | Demao Yang | Compositions and treatments using ex vivo activated cells for myelosuppressed patients |
CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
MX2007015942A (es) | 2005-07-01 | 2008-03-07 | Medarex Inc | Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada. |
EP2015765A4 (en) * | 2006-03-28 | 2011-11-23 | Neopro Labs Llc | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS |
ATE551071T1 (de) | 2006-09-08 | 2012-04-15 | Medimmune Llc | Humanisierte anti-cd19-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen |
DK2170959T3 (da) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | Antistoffer mod human programmeret dødsreceptor pd-1 |
EP2240204A1 (en) | 2008-02-04 | 2010-10-20 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
JP5794917B2 (ja) | 2008-09-12 | 2015-10-14 | アイシス・イノベーション・リミテッドIsis Innovationlimited | Pd−1特異抗体およびその使用 |
AU2009290544B2 (en) | 2008-09-12 | 2015-07-16 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
CN102264762B (zh) | 2008-09-26 | 2018-03-27 | 达纳-法伯癌症研究公司 | 人抗pd‑1、pd‑l1和pd‑l2的抗体及其应用 |
TWI686405B (zh) | 2008-12-09 | 2020-03-01 | 建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
RU2625034C2 (ru) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Антитела и другие молекулы, которые связывают в7-н1 и pd-1 |
WO2013177187A2 (en) | 2012-05-22 | 2013-11-28 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents |
US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
TR201808753T4 (tr) * | 2012-06-08 | 2018-07-23 | Alkermes Pharma Ireland Ltd | Agonistler ve antagonistler olarak dairesel permütasyon tarafından modifiye edilmiş ligandlar. |
ES2906615T3 (es) * | 2013-04-19 | 2022-04-19 | Cytune Pharma | Tratamiento derivado de citocinas con síndrome de fuga vascular reducido |
ES2792183T3 (es) | 2013-09-13 | 2020-11-10 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
MA40094B1 (fr) * | 2014-08-06 | 2022-05-31 | Univ Miami | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation |
JP6621478B2 (ja) * | 2014-12-19 | 2019-12-18 | アルカーメス,インコーポレイテッド | 一本鎖Fc融合タンパク質 |
CN106552259B (zh) * | 2015-09-24 | 2022-03-29 | 中国科学院上海巴斯德研究所 | 一种融合蛋白及其治疗疾病的用途 |
GB201712032D0 (en) * | 2017-07-26 | 2017-09-06 | Bioinvent Int Ab | Antibodies and uses thereof |
AU2018364752A1 (en) | 2017-11-13 | 2020-05-28 | Bioxcel Therapeutics, Inc. | Methods and compositions for treating cancer by modifying multiple arms of the immune system |
US20210038684A1 (en) | 2019-06-11 | 2021-02-11 | Alkermes Pharma Ireland Limited | Compositions and Methods for Cancer Immunotherapy |
-
2020
- 2020-06-10 US US16/898,008 patent/US20210038684A1/en active Pending
- 2020-06-10 US US16/897,920 patent/US11246906B2/en active Active
- 2020-06-11 AU AU2020292590A patent/AU2020292590A1/en active Pending
- 2020-06-11 CA CA3143097A patent/CA3143097A1/en active Pending
- 2020-06-11 CN CN202080056860.0A patent/CN114555126A/zh active Pending
- 2020-06-11 JP JP2021573568A patent/JP2022535610A/ja active Pending
- 2020-06-11 KR KR1020227000547A patent/KR20220044480A/ko unknown
- 2020-06-11 BR BR112021024966A patent/BR112021024966A2/pt unknown
- 2020-06-11 MA MA056176A patent/MA56176A/fr unknown
- 2020-06-11 JP JP2021573569A patent/JP2022535972A/ja active Pending
- 2020-06-11 MX MX2021015353A patent/MX2021015353A/es unknown
- 2020-06-11 MX MX2021015354A patent/MX2021015354A/es unknown
- 2020-06-11 WO PCT/EP2020/066234 patent/WO2020249693A1/en unknown
- 2020-06-11 BR BR112021025035A patent/BR112021025035A2/pt unknown
- 2020-06-11 WO PCT/EP2020/066226 patent/WO2020249687A1/en unknown
- 2020-06-11 KR KR1020227000553A patent/KR20220044481A/ko unknown
- 2020-06-11 CA CA3143098A patent/CA3143098A1/en active Pending
- 2020-06-11 CN CN202080055682.XA patent/CN114423446A/zh active Pending
- 2020-06-11 EP EP20732576.2A patent/EP3982998A1/en active Pending
- 2020-06-11 AU AU2020291109A patent/AU2020291109A1/en active Pending
- 2020-06-11 EP EP20732575.4A patent/EP3983530A1/en active Pending
-
2021
- 2021-12-07 IL IL288754A patent/IL288754A/en unknown
- 2021-12-07 IL IL288756A patent/IL288756A/en unknown
-
2022
- 2022-01-04 US US17/568,251 patent/US11980652B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2020249693A1 (en) | 2020-12-17 |
AU2020292590A1 (en) | 2022-02-03 |
CA3143097A1 (en) | 2020-12-17 |
CN114423446A (zh) | 2022-04-29 |
US20220241370A1 (en) | 2022-08-04 |
JP2022535972A (ja) | 2022-08-10 |
CA3143098A1 (en) | 2020-12-17 |
KR20220044480A (ko) | 2022-04-08 |
BR112021025035A2 (pt) | 2022-02-22 |
JP2022535610A (ja) | 2022-08-09 |
IL288756A (en) | 2022-02-01 |
AU2020291109A1 (en) | 2022-02-03 |
WO2020249687A1 (en) | 2020-12-17 |
IL288754A (en) | 2022-02-01 |
EP3982998A1 (en) | 2022-04-20 |
KR20220044481A (ko) | 2022-04-08 |
US11980652B2 (en) | 2024-05-14 |
EP3983530A1 (en) | 2022-04-20 |
MX2021015353A (es) | 2022-04-07 |
CN114555126A (zh) | 2022-05-27 |
MA56176A (fr) | 2022-04-20 |
US11246906B2 (en) | 2022-02-15 |
US20210038684A1 (en) | 2021-02-11 |
US20210052694A1 (en) | 2021-02-25 |
MX2021015354A (es) | 2022-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021024966A2 (pt) | Composições e métodos para administração subcutânea de imunoterapia de câncer | |
Abu Eid et al. | Enhanced therapeutic efficacy and memory of tumor-specific CD8 T cells by ex vivo PI3K-δ inhibition | |
AU2018275894A1 (en) | Articles of manufacture and methods for treatment using adoptive cell therapy | |
BR112019010020A2 (pt) | compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20 | |
CY1114912T1 (el) | Εμβολιο για την προληψη της υποτροπης του καρκινου του μαστου | |
MX2009003764A (es) | Preparaciones de celulas presentadoras de antigeno artificiales y su uso en terapias celulares. | |
BR112016000810A2 (pt) | imunoterapia contra vários tumores tais como câncer de pulmão, incluindo cpcnp | |
MX2020009773A (es) | Terapia de combinacion. | |
BRPI0516531A (pt) | imunoterapia de distúrbios auto-imunes | |
MX2010002002A (es) | Peptido foxm1 y agente medicinal que lo contiene. | |
Macciò et al. | Blocking inflammation to improve immunotherapy of advanced cancer | |
BR112022001148A2 (pt) | Células imunes modificadas, composição farmacêutica, kit, uso de uma célula imune modificada e invenção de produto | |
ES2965957T3 (es) | Una vacuna junto con un inhibidor del punto de control inmunitario para usar en el tratamiento del cáncer | |
BR112021024822A2 (pt) | Terapia de combinação de terapia citotóxica mediada por células e inibidor de proteína da família bcl2 pró-sobrevivência | |
BR112021022363A2 (pt) | Composições e métodos para fabricação de células t | |
Johnson et al. | Chemo-immunotherapy: role of indoleamine 2, 3-dioxygenase in defining immunogenic versus tolerogenic cell death in the tumor microenvironment | |
MX2020003129A (es) | Composiciones celulares que comprenden linfocitos t específicos para antígenos para una terapia adoptiva. | |
MX2023004032A (es) | Terapias inmuno-oncologicas con conjugados de il-2. | |
MX2020011817A (es) | Metodos para tratar el linfoma. | |
AU2018271862A1 (en) | Combination therapy | |
PH12021551047A1 (en) | Anti-ptk7 immune cell cancer therapy | |
MX2022003190A (es) | Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila. | |
ES2357548T3 (es) | Péptido poli-epitope derivado de timidilato sintasa que tiene actividad inmunológica y antitumoral. | |
AR122023A1 (es) | Péptidos y métodos para el tratamiento de esclerosis múltiple | |
WO2020142694A3 (en) | Ero1-alpha inhibitors |